Literature DB >> 15917535

Penetration of linezolid into soft tissues of healthy volunteers after single and multiple doses.

Pejman Dehghanyar1, Cornelia Bürger, Markus Zeitlinger, Florian Islinger, Florian Kovar, Markus Müller, Charlotte Kloft, Christian Joukhadar.   

Abstract

The present study tested the ability of linezolid to penetrate soft tissues in healthy volunteers. Ten healthy volunteers were subjected to linezolid drug intake at a dose of 600 mg twice a day for 3 to 5 days. The first dose was administered intravenously. All following doses were self-administered orally. The tissue penetration of linezolid was assessed by use of in vivo microdialysis. In the single-dose experiments the ratios of the area under the concentration-time curve from 0 to 8 h (AUC0-8) for tissue to the AUC0-8 for free plasma were 1.4+/-0.3 (mean+/-standard deviation) and 1.3+/-0.4 for subcutaneous adipose and muscle tissue, respectively. After multiple doses, the corresponding mean ratios were 0.9+/-0.2 and 1.0+/-0.5, respectively. The ratios of the AUC from 0 to 24 h (AUC0-24) for free linezolid in tissues to the MIC were between 50 and 100 for target pathogens with MICs between 2 and 4 mg/liter. In conclusion, the present study showed that linezolid penetrates rapidly into the interstitial space fluid of subcutaneous adipose and skeletal muscle tissues in healthy volunteers. On the basis of pharmacokinetic-pharmacodynamic calculations, we suggest that linezolid concentrations in soft tissues can be considered sufficient to inhibit the growth of many clinically relevant bacteria.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15917535      PMCID: PMC1140501          DOI: 10.1128/AAC.49.6.2367-2371.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  Relevance of soft-tissue penetration by levofloxacin for target site bacterial killing in patients with sepsis.

Authors:  M A Zeitlinger; P Dehghanyar; B X Mayer; B S Schenk; U Neckel; G Heinz; A Georgopoulos; M Müller; C Joukhadar
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

2.  Pharmacokinetics of telithromycin in plasma and soft tissues after single-dose administration to healthy volunteers.

Authors:  Rainer Gattringer; Eleonora Urbauer; Friederike Traunmüller; Markus Zeitlinger; Pejman Dehghanyar; Petra Zeleny; Wolfgang Graninger; Markus Müller; Christian Joukhadar
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

Review 3.  Microdialysis: current applications in clinical pharmacokinetic studies and its potential role in the future.

Authors:  Christian Joukhadar; Markus Müller
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  Concentrations of gemifloxacin at the target site in healthy volunteers after a single oral dose.

Authors:  Florian Islinger; Rene Bouw; Mathias Stahl; Edith Lackner; Petra Zeleny; Martin Brunner; Markus Müller; Hans Georg Eichler; Christian Joukhadar
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

Review 5.  Pharmacokinetics of antibiotics in natural and experimental superficial compartments in animals and humans.

Authors:  D M Ryan
Journal:  J Antimicrob Chemother       Date:  1993-05       Impact factor: 5.790

6.  Characterization of peripheral-compartment kinetics of antibiotics by in vivo microdialysis in humans.

Authors:  M Müller; O Haag; T Burgdorff; A Georgopoulos; W Weninger; B Jansen; G Stanek; H Pehamberger; E Agneter; H G Eichler
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

Review 7.  Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections.

Authors:  Alasdair P MacGowan
Journal:  J Antimicrob Chemother       Date:  2003-05       Impact factor: 5.790

8.  Development of a liquid chromatography method for the determination of linezolid and its application to in vitro and human microdialysis samples.

Authors:  Cornelia Buerger; Christian Joukhadar; Markus Muller; Charlotte Kloft
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2003-10-25       Impact factor: 3.205

9.  Application of microdialysis to clinical pharmacokinetics in humans.

Authors:  M Müller; R Schmid; A Georgopoulos; A Buxbaum; C Wasicek; H G Eichler
Journal:  Clin Pharmacol Ther       Date:  1995-04       Impact factor: 6.875

10.  Effect of protein binding on antibiotic activity in vivo.

Authors:  D J Merrikin; J Briant; G N Rolinson
Journal:  J Antimicrob Chemother       Date:  1983-03       Impact factor: 5.790

View more
  29 in total

1.  Simulated antibiotic exposures in an in vitro hollow-fiber infection model influence toxin gene expression and production in community-associated methicillin-resistant Staphylococcus aureus strain MW2.

Authors:  Solen Pichereau; Madhulatha Pantrangi; William Couet; Cedric Badiou; Gerard Lina; Sanjay K Shukla; Warren E Rose
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

2.  Increase of microcirculatory blood flow enhances penetration of ciprofloxacin into soft tissue.

Authors:  Christian Joukhadar; Pejman Dehghanyar; Friederike Traunmüller; Robert Sauermann; Bernhard Mayer-Helm; Apostolos Georgopoulos; Markus Müller
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

Review 3.  Microdialysis: current applications in clinical pharmacokinetic studies and its potential role in the future.

Authors:  Christian Joukhadar; Markus Müller
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis.

Authors:  Cornelia Buerger; Nele Plock; Pejman Dehghanyar; Christian Joukhadar; Charlotte Kloft
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

Review 5.  Interethnic differences in pharmacokinetics of antibacterials.

Authors:  Danny Tsai; Janattul-Ain Jamal; Joshua S Davis; Jeffrey Lipman; Jason A Roberts
Journal:  Clin Pharmacokinet       Date:  2015-03       Impact factor: 6.447

Review 6.  Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents.

Authors:  Daniel Gonzalez; Stephan Schmidt; Hartmut Derendorf
Journal:  Clin Microbiol Rev       Date:  2013-04       Impact factor: 26.132

7.  Determination of tissue penetration and pharmacokinetics of linezolid in patients with diabetic foot infections using in vivo microdialysis.

Authors:  Dora E Wiskirchen; Ashley Shepard; Joseph L Kuti; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2011-06-27       Impact factor: 5.191

8.  Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients.

Authors:  Iris K Minichmayr; André Schaeftlein; Joseph L Kuti; Markus Zeitlinger; Charlotte Kloft
Journal:  Clin Pharmacokinet       Date:  2017-06       Impact factor: 6.447

9.  Pilot investigation on long-term subcutaneous microdialysis: proof of principle in humans.

Authors:  Franziska Simmel; Claudia Kirbs; Zeynep Erdogan; Edith Lackner; Markus Zeitlinger; Charlotte Kloft
Journal:  AAPS J       Date:  2012-10-13       Impact factor: 4.009

10.  Characterization of 22 Antituberculosis Drugs for Inhibitory Interaction Potential on Organic Anionic Transporter Polypeptide (OATP)-Mediated Uptake.

Authors:  M Masud Parvez; Jin Ah Jung; Ho Jung Shin; Dong Hyun Kim; Jae-Gook Shin
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.